• Kineta Inc., of Seattle, received a $2.8 million Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease to support work on a new class of antiviral drugs. Kineta's program focuses on agonists of the retinoic acid inducible gene 1 innate immune pathway and is designed to target RNA viruses such as hepatitis C, influenza, West Nile virus, respiratory syncytial virus, Dengue fever and the common cold.